Antidepressants are medications prescribed primarily to manage major depressive disorder, anxiety disorders, and related mental health conditions. While psychiatrists and medical officers take the lead in prescribing these drugs, midwives in Nigeria frequently encounter pregnant and postnatal women experiencing significant psychological distress. Depression and anxiety during the perinatal period are common, affecting maternal wellbeing, fetal development, and early mother-infant bonding. Understanding the basics of psychopharmacology enables midwives to recognize treatment regimens, support compliant care, and identify potential drug interactions or warning signs early.
Various classes of antidepressants exist, each working differently within the central nervous system to alter neurotransmitter levels such as serotonin, norepinephrine, and dopamine.
Perinatal mental health conditions demand careful clinical evaluation. Untreated severe depression carries profound risks, including poor antenatal nutrition, substance misuse, suicidal ideation, preeclampsia, and impaired maternal-infant bonding. Midwives must weigh these risks against the potential risks of fetal drug exposure. Antidepressant therapy is generally indicated for moderate to severe major depressive disorder, panic disorder, obsessive-compulsive disorder, and severe postpartum depression that does not respond to psychotherapy or supportive counseling alone.
Most antidepressants are lipophilic molecules that readily cross the human placenta and enter the fetal circulation. During the third trimester, fetal exposure raises specific concerns regarding neonatal adaptation. Newborns whose mothers took SSRIs close to delivery may exhibit poor neonatal adaptation syndrome, characterized by jitteriness, mild respiratory distress, weak crying, and feeding difficulties. These symptoms are generally self-limiting and resolve within a couple of weeks with supportive neonatal care. Congenital malformation risks are also evaluated, though most modern SSRIs show no clear evidence of major teratogenicity.
Antidepressants cause various systemic side effects that can impact compliance. Common initial complaints include dry mouth, nausea, dizziness, sexual dysfunction, and sleep disturbances. Midwives should monitor women closely during the first two weeks of initiation when side effects peak and before therapeutic mood benefits emerge. Additionally, clinicians must screen for the rare induction of manic episodes in patients with undiagnosed bipolar disorder, as well as monitor for emerging thoughts of self-harm during early treatment adjustment phases.
Postnatal treatment often involves balancing the benefits of breastfeeding with infant drug exposure via breast milk. Most SSRIs, particularly sertraline, pass into breast milk in very small quantities and are considered compatible with lactation. Midwives advise mothers to observe their breastfed infants for unusual sedation, poor weight gain, or irritability. Serum concentrations in the infant are generally far below therapeutic levels, making breastfeeding safe for the majority of women maintained on standard, single-agent antidepressant therapies.
Adherence is a major hurdle in antidepressant therapy because therapeutic effects take two to four weeks to become noticeable, while side effects appear immediately. Midwives bridge the communication gap between women and medical prescribers by offering reassurance, explaining the timeline of recovery, and dispelling local cultural myths about mental health medications. Encouraging open dialogue ensures that patients do not abruptly stop their medication out of frustration or fear, thereby reducing the risk of relapse or discontinuation syndrome.